iHuman Inc. IH
Other Consumer Services · IPO 2020 · data as of November 13, 2026
iHuman Inc. (IH) is a real estate company listed in the US with a market value of about $51M. In fiscal year 2025 it had revenue of $115M and net income of $14M, a net margin of 11.8%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is financial health (5/5); the weakest is track record (0/5).
Key numbers: a P/E of 3.7, a price to free cash flow of 7.6, 5-year revenue growth of 7% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 74% above the current price.
About iHuman
iHuman is listed in the US and classified in other consumer services, IPO year 2020. Revenue went from $82M in 2020 to $115M in 2025, growth of about 7.2% a year. It was profitable in 4 of the last 6 years in our data. It spends 26% of revenue on research and development.
Score: 2.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $115M | $126M | $143M | $143M | $148M | $82M |
| Net income | $14M | $14M | $25M | $16M | -$6M | -$6M |
| Free cash flow | $7M | $7M | $23M | $26M | $930000 | $32M |
| EPS (diluted) | $0.27 | $0.26 | $0.50 | $0.31 | $-0.11 | $-0.11 |
| Net margin | 11.8% | 10.7% | 17.8% | 11.1% | -3.9% | -7.0% |
| ROIC | 6.2% | 6.6% | 14.8% | 11.9% | -8.4% | -5.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is iHuman’s P/E ratio?
About 3.7, based on the last twelve months of diluted earnings per share.
Is iHuman stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 74% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does iHuman pay a dividend?
Yes. The dividend yield is about 11.05%, and it has paid dividends for 2 years in our data.
Is iHuman a good stock to buy?
We do not give buy or sell advice. iHuman scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.